A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
Phase 2
Completed
- Conditions
- Platinum-Sensitive Ovarian Cancer in First Relapse
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT02289950
A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02279485
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT02249078
A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02222324
To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT02220972
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
- Conditions
- Differentiated Thyroid Cancer
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT02211222
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02207790
A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02199379
A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02199392
A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: placebo-ketoconazoleDrug: ketoconazole-placebo
- First Posted Date
- 2014-07-23
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02198170
© Copyright 2025. All Rights Reserved by MedPath